FOLH1 and posterior cortical atrophy: The encouraging results in terms of the clinical outcome and safety of [177Lu]Lu-PSMA-617 observed in mCRPC patients treated with [177Lu]Lu-PSMA after three lines of therapies set the ground for an application of PSMA-targeted therapy in the earlier stage of PCa, included as a neo-adjuvant therapy before radical prostatectomy.